Proclara Biosciences Stock

proclarabio.comHealthcare / BioTech & PharmaFounded: 2006Funding to Date: $112.79MM

Developer of disease-modifying therapies intended to be used for the treatment of neurodegenerative diseases. The company's therapies develop novel therapies that recognize and target multiple misfolded proteins, enabling clinicians to make a transformative impact on the lives of patients affected by Alzheimer's, Parkinson's and systemic amyloidosis.

Register To Buy and Sell Shares

For more details on financing and valuation for Proclara Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Proclara Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Proclara Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Hampus Hillerstrom
Executive Vice President, Co-Founder & Chief Financial Officer
David Michelson MD
Chief Medical Officer & Board Member
Beka Solomon Ph.D
Scientific Founder & Member, Scientific Advisory Board
Jonathan Solomon
Co-Founder and Board Member
Richard Fisher
Chief Executive Officer, President & Board Member

Board Members

David Michelson MD
Jonathan Solomon
Nick Leschly
Paul Goldenheim MD
Valérie Calenda Ph.D
Mérieux Développement
François Valencony
Mérieux Développement
Franz Hefti Ph.D
Kenneth Buckfire
Peter Smedvig
Saira Ramasastry
Daniel Lynch
Hans Schoepflin
Beka Solomon Ph.D
Nico Dosenbach Ph.D
Richard Fisher
Vicki Sato Ph.D

Frequently Asked Questions About Proclara Biosciences’ Stock

plusminus
Can you buy Proclara Biosciences’ stock?
Proclara Biosciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy Proclara Biosciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Proclara Biosciences’ stock?
Yes, you can sell stock of a private company like Proclara Biosciences. Forge can help you sell your Proclara Biosciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Proclara Biosciences’ stock price?
Proclara Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Proclara Biosciences’ private market stock price with Forge Data.
plusminus
What is Proclara Biosciences’ stock ticker symbol?
Proclara Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Proclara Biosciences Secures $47M in Series E Financing |FinSMEs
Proclara Biosciences, a Cambridge, MA-based biotechnology company developing novel therapies for diseases caused by protein misfolding, secured $47m in Series E financing. The round was led by existing investors including private investors and Merieux Developpement. As part of the Series E financing, Daniel Lynch, an experienced biotechnology executive and a venture partner at Third Rock Ventures, …
Updated on: Apr 13, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.